<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9715838" created="24/06/2006" creator="Noriko Katsu"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>9715838</PMID>
<Article>
<ArticleTitle>
<sentence id="S1">Inhibition of <term id="T1" lex="HIV-1_replication" sem="Other"><term id="T2" lex="HIV-1" sem="Virus">HIV-1</term> replication</term> by combination of a <term id="A1" sem="Organic_compound_other"><term id="T3" lex="novel_inhibitor" sem="Organic_compound_other">novel inhibitor</term> of <term id="T4" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term></term> with <term id="T5" lex="AZT" sem="Organic_compound_other">AZT</term>.</sentence>
<event KT="Investigation" id="E1">
<type class="Negative_regulation"/>
<theme idref="E2"/>
<cause idref="A1"/>
<cause idref="T5"/>
<clue><clueType>Inhibition</clueType> <linkTheme>of</linkTheme> HIV-1 replication <linkCause>by</linkCause> combination of a novel inhibitor of TNF-alpha with AZT.</clue>
<comment>TPS: A1</comment></event>
<event KT="Investigation" id="E28">
<type class="Negative_regulation"/>
<theme idref="E2"/>
<cause idref="T5"/>
<clue><clueType>Inhibition</clueType> <linkTheme>of</linkTheme> HIV-1 replication <linkCause>by</linkCause> combination of a novel inhibitor of TNF-alpha with AZT.</clue>
</event>
<event KT="Other" id="E29">
<type class="Correlation"/>
<theme idref="E1"/>
<theme idref="E28"/>
<clue>Inhibition of HIV-1 replication by <clueType>combination</clueType> <linkTheme>of</linkTheme> a novel inhibitor of TNF-alpha <linkTheme>with</linkTheme> AZT.</clue>
</event>
<event KT="Other" id="E2">
<type class="Viral_life_cycle"/>
<theme idref="T2"/>
<clue>Inhibition of HIV-1 <clueType>replication</clueType> by combination of a novel inhibitor of TNF-alpha with AZT.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">The <term id="T6" lex="small_molecule_S9a" sem="Organic_compound_other">small molecule S9a</term> was derived from an established <term id="T7" lex="tumor_necrosis_factor-alpha_(TNF-alpha)_inhibitor" sem="Organic_compound_other"><term id="T8" lex="tumor_necrosis_factor-alpha" sem="Protein_molecule">tumor necrosis factor-alpha</term> (<term id="T9" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term>) inhibitor</term> (<term id="T10" lex="Canventol" sem="Organic_compound_other">Canventol</term>) by replacement of the <term id="T11" lex="isopropylidine_group" sem="Organic_compound_other">isopropylidine group</term> with a <term id="T12" lex="phenyl_ring" sem="Organic_compound_other">phenyl ring</term>.</sentence>
<sentence id="S3"><term id="A2" sem="Organic_compound_other">S9a</term> at 10 to 100 nM inhibited <term id="T13" lex="HIV_production" sem="Other"><term id="A3" sem="Virus">HIV</term> production</term> as potently as <term id="T14" lex="3&apos;-azido-3&apos;-deoxythymidine" sem="Organic_compound_other">3&apos;-azido-3&apos;-deoxythymidine</term> (<term id="T15" lex="AZT" sem="Organic_compound_other">AZT</term>), an inhibitor of <term id="T16" lex="viral_reverse_transcriptase" sem="Protein_family_or_group">viral reverse transcriptase</term>.</sentence>
<event Manner="High" id="E4">
<type class="Negative_regulation"/>
<theme idref="E5"/>
<cause idref="A2"/>
<clue>S9a at 10 to 100 nM <clueType>inhibited</clueType> HIV production as <clueManner>potently</clueManner> as 3&apos;-azido-3&apos;-deoxythymidine (AZT), an inhibitor of viral reverse transcriptase.</clue>
</event>
<event KT="Other" id="E5">
<type class="Viral_life_cycle"/>
<theme idref="A3"/>
<clue>S9a at 10 to 100 nM inhibited HIV <clueType>production</clueType> as potently as 3&apos;-azido-3&apos;-deoxythymidine (AZT), an inhibitor of viral reverse transcriptase.</clue>
</event>
<event id="E6">
<type class="Negative_regulation"/>
<theme idref="E5"/>
<cause idref="T15"/>
<clue>S9a at 10 to 100 nM <clueType>inhibited</clueType> HIV production as potently as 3&apos;-azido-3&apos;-deoxythymidine (AZT), an inhibitor of viral reverse transcriptase.</clue>
<comment>CAUTION: SEE</comment></event>
<event KT="Fact" id="E7">
<type class="Negative_regulation"/>
<theme idref="T16"/>
<cause idref="T15"/>
<clue>S9a at 10 to 100 nM inhibited HIV production as potently as 3&apos;-azido-3&apos;-deoxythymidine (AZT), an <clueType>inhibitor</clueType> <linkTheme>of</linkTheme> viral reverse transcriptase.</clue>
</event>
<sentence id="S4">Furthermore, <term id="A4" sem="Organic_compound_other">S9a</term> and <term id="T17" lex="AZT" sem="Organic_compound_other">AZT</term> in combination, at <term id="T18" lex="noncytoxic_concentration" sem="Other">noncytoxic concentrations</term> strongly inhibited <term id="T19" lex="HIV-1_replication" sem="Other"><term id="T20" lex="HIV-1" sem="Virus">HIV-1</term> replication</term> that was more than additive and substantially prolonged the appearance of virus both in <term id="T21" lex="acutely_infected_CD4+_lymphocyte" sem="Cell_natural">acutely infected CD4+ lymphocytes</term> (<term id="T22" lex="SupT" sem="Cell_cultured">SupT</term>) in culture and in <term id="T23" lex="peripheral_blood_mononuclear_cell" sem="Cell_natural">peripheral blood mononuclear cells</term> (<term id="T24" lex="PBMC" sem="Cell_natural">PBMCs</term>) infected with a <term id="T25" lex="primary_HIV-1_isolate" sem="Virus">primary <term id="T26" lex="HIV-1" sem="Virus">HIV-1</term> isolate</term>.</sentence>
<event Manner="High" id="E8">
<type class="Negative_regulation"/>
<theme idref="E9"/>
<cause idref="A4"/>
<cause idref="T17"/>
<clue>Furthermore, S9a and AZT <linkCause>in combination</linkCause>, at noncytoxic concentrations <clueManner>strongly</clueManner> <clueType>inhibited</clueType> HIV-1 replication that was <clueType>more than additive</clueType> and substantially prolonged the appearance of virus both in acutely infected CD4+ lymphocytes (SupT) in culture and in peripheral blood mononuclear cells (PBMCs) infected with a primary HIV-1 isolate.</clue>
</event>
<event KT="Other" id="E9">
<type class="Viral_life_cycle"/>
<theme idref="T20"/>
<clue>Furthermore, S9a and AZT in combination, at noncytoxic concentrations strongly inhibited HIV-1 <clueType>replication</clueType> that was more than additive and substantially prolonged the appearance of virus both in acutely infected CD4+ lymphocytes (SupT) in culture and in peripheral blood mononuclear cells (PBMCs) infected with a primary HIV-1 isolate.</clue>
</event>
<event id="E10">
<type class="Positive_regulation"/>
<theme idref="E11"/>
<cause idref="A4"/>
<cause idref="T17"/>
<clue>Furthermore, S9a and AZT <linkCause>in combination</linkCause>, at noncytoxic concentrations strongly inhibited HIV-1 replication that was more than additive and substantially <clueType>prolonged</clueType> the appearance of virus both in acutely infected CD4+ lymphocytes (SupT) in culture and in peripheral blood mononuclear cells (PBMCs) infected with a primary HIV-1 isolate.</clue>
</event>
<event CL="L2" KT="Analysis" id="E11">
<type class="Viral_life_cycle"/>
<theme idref="T20"/>
<clue>Furthermore, S9a and AZT in combination, at noncytoxic concentrations strongly inhibited HIV-1 replication that was more than additive and substantially prolonged the <clueType><clueKT><clueCL>appearance</clueCL></clueKT></clueType> <linkTheme>of</linkTheme> <corefTheme>virus</corefTheme> both <clueLoc>in acutely infected CD4+ lymphocytes (SupT) in culture</clueLoc> and in peripheral blood mononuclear cells (PBMCs) infected with a primary HIV-1 isolate.</clue>
</event>
<event CL="L2" KT="Analysis" id="E3">
<type class="Viral_life_cycle"/>
<theme idref="T20"/>
<clue>Furthermore, S9a and AZT in combination, at noncytoxic concentrations strongly inhibited HIV-1 replication that was more than additive and substantially prolonged the <clueType><clueKT><clueCL>appearance</clueCL></clueKT></clueType> <linkTheme>of</linkTheme> <corefTheme>virus</corefTheme> both in acutely infected CD4+ lymphocytes (SupT) in culture and <clueLoc>in peripheral blood mononuclear cells (PBMCs) infected with a primary HIV-1 isolate</clueLoc>.</clue>
</event>
<event KT="Other" Manner="High" id="E12">
<type class="Initiation_of_viral_infection"/>
<theme idref="T20"/>
<theme idref="T22"/>
<clue>Furthermore, S9a and AZT in combination, at noncytoxic concentrations strongly inhibited HIV-1 replication that was more than additive and substantially prolonged the appearance of virus both in <clueManner>acutely</clueManner> <clueType>infected</clueType> CD4+ lymphocytes (SupT) in culture and in peripheral blood mononuclear cells (PBMCs) infected with a primary HIV-1 isolate.</clue>
</event>
<event KT="Other" id="E13">
<type class="Initiation_of_viral_infection"/>
<theme idref="T26"/>
<theme idref="T24"/>
<clue>Furthermore, S9a and AZT in combination, at noncytoxic concentrations strongly inhibited HIV-1 replication that was more than additive and substantially prolonged the appearance of virus both in acutely infected CD4+ lymphocytes (SupT) in culture and in peripheral blood mononuclear cells (PBMCs) <clueType>infected</clueType> <linkTheme>with</linkTheme> a primary HIV-1 isolate.</clue>
</event>
<sentence id="S5"><term id="A5" sem="Organic_compound_other">S9a</term> inhibited <term id="A6" sem="Protein_molecule"><term id="T28" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term> promoter</term>-driven <term id="T27" sem="Other"><term id="T29" lex="reporter_gene" sem="DNA_family_or_group">reporter gene</term> activity</term>.</sentence>
<event id="E14">
<type class="Negative_regulation"/>
<theme idref="E15"/>
<cause idref="A5"/>
<clue>S9a <clueType>inhibited</clueType> TNF-alpha promoter-driven reporter gene activity.</clue>
</event>
<event KT="Other" id="E15">
<type class="Positive_regulation"/>
<theme idref="T29"/>
<cause idref="A6"/>
<clue>S9a inhibited TNF-alpha promoter-<clueType>driven</clueType> reporter gene activity.</clue>
</event>
<sentence id="S6">It was proposed that the mechanism of <term id="T30" lex="antiviral_action" sem="Other">antiviral action</term> of <term id="T31" lex="S9a" sem="Organic_compound_other">S9a</term> was on the host cell, by blocking <term id="T32" lex="TNF-alpha_transcription" sem="Other"><term id="A12" sem="DNA_domain_or_region"><term id="T33" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term></term> transcription</term> via a <cons id="C1" lex="(AND Tat-induced_loop tar-independent_loop)" sem="(AND Other Other)"><frag id="F1">Tat</frag><frag id="F2">-induced</frag> <frag id="F3">tar-independent</frag> <frag id="F4">loop</frag></cons>, which decreases downstream <term id="T36" lex="NF-kappaB_activation" sem="Other"><term id="T37" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> activation</term> of <term id="T38" lex="HIV-1_long_terminal_repeat" sem="DNA_domain_or_region"><term id="T39" lex="HIV-1" sem="Virus">HIV-1</term> long terminal repeat</term> (<term id="T40" lex="LTR" sem="DNA_domain_or_region">LTR</term>).</sentence>
<event CL="L2" KT="Analysis" id="E16" uncertainty="probable">
<type class="Negative_regulation"/>
<cause idref="E17"/>
<clue>It was <clueKT><clueCL>proposed</clueCL></clueKT> that the mechanism of <clueType>antiviral action</clueType> of S9a was <clueLoc>on the host cell</clueLoc>, <linkCause>by</linkCause> blocking TNF-alpha transcription via a Tat-induced tar-independent loop, which decreases downstream NF-kappaB activation of HIV-1 long terminal repeat (LTR).</clue>
<comment>NO THEME</comment></event>
<event KT="Other" id="E17" uncertainty="probable">
<type class="Negative_regulation"/>
<theme idref="E18"/>
<cause idref="T31"/>
<clue>It was proposed that the mechanism of antiviral action of S9a was on the host cell, by <clueType>blocking</clueType> TNF-alpha transcription via a Tat-induced tar-independent loop, which decreases downstream NF-kappaB activation of HIV-1 long terminal repeat (LTR).</clue>
</event>
<event KT="Other" id="E18">
<type class="Transcription"/>
<theme idref="A12"/>
<clue>It was proposed that the mechanism of antiviral action of S9a was on the host cell, by blocking TNF-alpha <clueType>transcription</clueType> via a Tat-induced tar-independent loop, which decreases downstream NF-kappaB activation of HIV-1 long terminal repeat (LTR).</clue>
</event>
<event KT="Other" id="E31">
<type class="Positive_regulation"/>
<theme idref="E18"/>
<cause idref="E27"/>
<clue>It was proposed that the mechanism of antiviral action of S9a was on the host cell, by blocking TNF-alpha transcription <linkCause>via</linkCause> a Tat-induced tar-independent loop, which decreases downstream NF-kappaB activation of HIV-1 long terminal repeat (LTR).</clue>
</event>
<event KT="Other" id="E27">
<type class="Positive_regulation"/>
<theme idref="E17"/>
<cause idref="F1"/>
<clue>It was proposed that the mechanism of antiviral action of S9a was on the host cell, by blocking TNF-alpha transcription via a Tat-<clueType>induced</clueType> <corefTheme>tar-independent loop</corefTheme>, which decreases downstream NF-kappaB activation of HIV-1 long terminal repeat (LTR).</clue>
</event>
<event KT="Other" id="E19">
<type class="Negative_regulation"/>
<theme idref="E20"/>
<cause idref="E17"/>
<clue>It was proposed that the mechanism of antiviral action of S9a was on the host cell, by blocking TNF-alpha transcription via a Tat-induced tar-independent loop, which <clueType>decreases</clueType> <linkTheme>downstream</linkTheme> NF-kappaB activation of HIV-1 long terminal repeat (LTR).</clue>
</event>
<event KT="Other" id="E20">
<type class="Positive_regulation"/>
<theme idref="T40"/>
<cause idref="T37"/>
<clue>It was proposed that the mechanism of antiviral action of S9a was on the host cell, by blocking TNF-alpha transcription via a Tat-induced tar-independent loop, which decreases downstream NF-kappaB <clueType>activation</clueType> <linkTheme>of</linkTheme> HIV-1 long terminal repeat (LTR).</clue>
</event>
<sentence id="S7"><term id="T41" lex="S9a" sem="Organic_compound_other">S9a</term> was superior to the first generation compound <term id="T42" lex="Canventol" sem="Organic_compound_other">Canventol</term>, which was superior to the natural compound <term id="T43" lex="sarcophytol_A" sem="Organic_compound_other">sarcophytol A</term>, demonstrating that further <term id="T44" lex="structure-based_enhancement" sem="Other">structure-based enhancement</term> of potency of these compounds is feasible.</sentence>
<sentence id="S8">This study suggests a therapeutic approach against <term id="T45" lex="AIDS" sem="Other">AIDS</term> by application of two <term id="A11" sem="Organic_compound_other">drugs</term>, one against a <term id="A7" sem="Cell_natural">cellular</term> and the other a <term id="A8" sem="Virus">viral</term> target, which may provide an approach to the problem of frequent emergence of <term id="T46" lex="resistant_variant" sem="Virus">resistant <term id="A10" sem="Virus">variants</term></term> to combinations of <term id="A9" sem="Organic_compound_other">drugs</term> that target only <term id="T47" lex="HIV_gene" sem="DNA_family_or_group">HIV genes</term>.</sentence>
<event KT="Method" id="E22">
<type class="Artificial_process"/>
<theme idref="A11"/>
<theme idref="A7"/>
<clue>This study suggests a therapeutic approach against AIDS by <clueType>application</clueType> <linkTheme>of</linkTheme> <corefTheme>two drugs</corefTheme>, one <linkTheme>against</linkTheme> a cellular and the other a viral target, which may provide an approach to the problem of frequent emergence of resistant variants to combinations of drugs that target only HIV genes.</clue>
</event>
<event KT="Method" id="E30">
<type class="Artificial_process"/>
<theme idref="A11"/>
<theme idref="A8"/>
<clue>This study suggests a therapeutic approach against AIDS by <clueType>application</clueType> <linkTheme>of</linkTheme> <corefTheme>two drugs</corefTheme>, one <linkTheme>against</linkTheme> a cellular and the other a viral target, which may provide an approach to the problem of frequent emergence of resistant variants to combinations of drugs that target only HIV genes.</clue>
</event>
<event KT="Fact" Polarity="Negative" assertion="non-exist" id="E25">
<type class="Negative_regulation"/>
<theme idref="A10"/>
<cause idref="E26"/>
<clue>This study suggests a therapeutic approach against AIDS by application of two drugs, one against a cellular and the other a viral target, which may provide an approach to the problem of frequent emergence of <clueType><cluePolarity>resistant</cluePolarity></clueType> variants <linkCause>to</linkCause> combinations of drugs that target only HIV genes.</clue>
</event>
<event KT="Other" id="E26">
<type class="Regulation"/>
<theme idref="T47"/>
<cause idref="A9"/>
<clue>This study suggests a therapeutic approach against AIDS by application of two drugs, one against a cellular and the other a viral target, which may provide an approach to the problem of frequent emergence of resistant variants to <linkCause>combinations of</linkCause> drugs that <clueType>target</clueType> only HIV genes.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
